• Some aspects of the role of chemotherapy in the treatment of patients with recurrent ovarian cancer
To content

Some aspects of the role of chemotherapy in the treatment of patients with recurrent ovarian cancer

HEALTH OF WOMAN. 2015.9(105):148–151
 

Some aspects of the role of chemotherapy in the treatment of patients with recurrent ovarian cancer
 

Kharchenko K., Ponomariova O., Vakulenko G.

Kyiv city clinical cancer center

A.A. Bogomolets National Medical University, Kiev
 

The current approach to the treatment of recurrent ovarian cancer is multi-modal. The main role in the treatment belongs to two methods: surgical and drug. To date, questions concerning tactics, phasing and duration of treatment, and the optimal chemotherapy regimens, remain unresolved. In modern clinical setting many new drugs being tested, examined the effectiveness of a combination there of. The article presents the literature data on the use of various chemotherapeutic prepraty in the treatment of relapse of ovarian cancer and their effectiveness.
 

Key words: treatment of recurrent ovarian cancer, chemotherapy for recurrent ovarian cancer.
 

REFERENCES

1. Тюляндин СА, Моисеенко ВМ. 2004. Рак яичников: химиотерапия второй линии. Практическая онкология: избранные лекции. СПб, Центр ТОММ:359–368.

2. Bookman MA, Brady MF, McGuire WP et al. 2009. Evaluation of new platinum-based treatment regiments in advanced-stage ovarian cancer: a phase III trial of the gynecologic cancer intergroup. J Clin Oncol. 27(9):1419-25. http://dx.doi.org/10.1200/JCO.2008.19.1684; PMid:19224846 PMCid:PMC2668552

3. Bookman MA. 1999. Extending the platinum-free interval in recurrent ovarian cancer: the role of topotecan in second-line chemotherapy. The Oncologist. 4(2):87-94.

4. Горбунова АВ. 2001. Повторные циторедуктивные операции и вторая линия химиотерапии при лечении рецидивов рака яичников: Дис. канд. мед. наук: 14.00.14. М:132–150.

5. Горбунова ВА. 2002. Топотекан в качестве II линии химиотерапии рака яичников. Совр. онкол. 4;4:172–174.

6. Bookman MA, Malmstrom H, Bolis G et al. 1998. Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. J. Clin. Oncol. 16;10:3345–3352.

7. Boente MP, Schilder R, Ozols RF. 1997. Gynecologic cancers. Cancer Chemother. Biol. Response Modif. 17:536–56.

8. Cantu MG, Buda A, Parma G et al. Randomized controlled trial of single- agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum- based regimens. J Clin Oncol. 20(5):1232–7.

9. Chan JK, Tian C, Monk ВJ et al. 2008. Prognostic factors for high-risk early-stage epithelial ovarian cancer: a Gynecologic Oncology Group study. Cancer. 15:2202–10. http://dx.doi.org/10.1002/cncr.23390; PMid:18348296

10. Carmical et al. 1996. Chemotherapy of recurrent ovarian cancer. ASCO. 7:765–766.

11. Downs LS, Judson PL, Argenta PA et al. 2008, Jan 15. A prospective randomized trial of thalidomide with topotecan compared with topotecan alone in women with recurrent epithelial ovarian carcinoma. Cancer. 331–9.

12. Du Bois A, Lueck HJ, Meerpohl HG. 1997. Recurrent and 2nd line therapy in ovarian carcinoma: an overview of conventional systemic therapy modalities. Zentralbl. Gynakol. 119(7):299–323.

13. Du Bois A, Lueck HJ, Meier W et al. 1999. Cisplatin/paclitaxel vs carboplatin/paclitaxel in ovarian cancer. ASCO. 18:1374.

14. Einzig AI, Wiernik PH, Sasloff J et al. 1992. Phase II study and long-term follow-up of patients treated with taxol for advanced ovarian adenocarcinoma. Clin. Oncol. 10;11:1748–1753.

15. Eisenhauer E, Abu-Rustin NR, Sonoda Y et al. 2006. The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIc-IV epithelial ovarian cancer. Gynaecol. Oncol. 103;3:1083–1090. http://dx.doi.org/10.1016/j.ygyno.2006.06.028; PMid:16890277

16. Eisenhauer E, Swenerton KD, Sturgeon JF et al. 1990. Carboplatin therapy for recurrent ovarian carcinoma: National Cancer Institute of Canada experience and a review of the literature. Current Perspectives and Future Directions. – Philadelphia, PA: W.B. Saunders Company:133–140.

17. Fung-Kee-Fung M, Oliver T, Elit L et al. 2007, Oct. Optimal chemotherapy treatment for women with recurrent ovarian cancer. Our Oncol. 14(5):195–208.

18. Gordon AN, Fleagle JT, Guthrie D et al. 2001, Jul 15. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. Clin Oncol. 19(14):3312–22.

19. Hauge MD, Long HJ, Hartmann LC et al. 1992. Phase II trial of intravenous hexamethylmelamine in patients with advanced ovarian cancer. Invest. New Drags. 10;4:299–301. http://dx.doi.org/10.1007/BF00944184

20. Ito K, Koyama M, Adachi S et al. 1999. A pilot study of taxol+ CBDCA for recurrent ovarian cancer. ASCO. 18:1452.

21. Kato Y, Katsumata N. 2007, Jul. Ovarian cancer from the standpoint of medical oncology. Gan To Kagaku Ryoho. 34(7):1017–21.

22. Оskay-Oezcelik G, Koensgen D, Hindenburg HJ et al. 2008. Ovarian Cancer Study Group of the North-Eastern Germany Society of Gynecological Oncology (NOGGO). Biweekly pegylated liposomal doxorubicin as second-line treatment in patients with relapsed ovarian cancer after failure of platinum and paclitaxel: results from a multi-center phase II study of the NOGGOV. Anticancer Res. 28:1329–34.

23. Parmar MK, Ledermann JA, Colombo N et al. 2003. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/ AGO-OVAR-2.2 trial. Lancet. 361;9375:2099–2106.

24. Ten Bokkel Huinink W, Gore M, Cannichael J et al. 1997. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J. Clin. Oncol. 15;6:2183–2193.

25. Van der Burg MX, de Wit R, Stoter G et al. 1998. Phase II study if weekly cisplatin and weekly or 4-weekly taxol: a highly active regimen in advanced epithelial ovarian cancer. ASCO. 17:1370.

26. Monk BJ, Herzog T, Kaye S et al. 2008. A randomized phase III study of trabectedin with pegylated liposomal doxorubicin versus PLD in relapsed, recurrent ovarian cancer. Proceedings of the 33rd Annual Meeting of the European Society of Medical Oncology. Stockholm. Abstr. LBA3.

27. Черкасова МВ, Хохлова СВ, Лимарева СВ и др. 2013. Эффективность препарата трабектедин в монотерапии и комбинированных режимах в терапии распространенного рака яичника. Современная онкология 04:56–58.